Download - Ivi brochure 2004
Vaccines, Childrenand a Better World
p 3 .......Letter from the Director
p 4 .......Goal and Mission
The IVI and the Millenium Development Goals
p 5 .......Historical Landmarks
p 6 .......Board of Trustees
p 7 .......Scientific Advisory Group
p 8 .......Signatory Countries
Recent Growth
p 9 .......The IVI's Achievements
Organizational Structure
p 10 .....Divisions of the IVI
Translational Research Division
Laboratory Sciences Division
Training and Technical Assistance Division
p 15 .....Future Directions of the IVI
p 16 .....Donors to the IVI
Korea Support Committee
p 17 .....International Collaborators
Contents
Dr. John D. Clemens, Director of the IVI, is an international expert on vaccine evaluation in
developing countries. Before joining the IVI in 1999, he held senior positions at the United States
National Institutes of Health. He has been a long-term advisor to the World Health Organization(WHO)
and serves in a continuing appointment as an adjunct professor at Johns Hopkins University
Dear Friends,We live in an extraordinarily exciting era in which the fruits of biotechnology offer the prospect of new vaccines against diseases for which no
previous vaccines existed and of vastly improved versions of existing vaccines. While this revolution in vaccinology provides breathtaking
prospects for disease prevention, it is sobering to note that many vaccines that are routine public-health tools for the industrialized world are not
used in programs for the poor in the developing world, and that the discovery of vaccines against diseases that primarily afflict the developing
world has been painfully slow due to a lack of economic incentives.
The International Vaccine Institute (IVI), located in Seoul, the Republic of Korea, was established to assist efforts to close the gap between
vaccines for the developing world versus the industrialized world by conducting research and delivering technical assistance. The IVI is the world's
only international research organization devoted solely to bringing new vaccines to the poor populations of the developing world. To date, 35
countries and the WHO have signed the IVI Establishment Agreement.
The work and the growth of the IVI is part of a larger revolution in public-sector commitment to close the gap between vaccines for the rich and the
poor. The Global Alliance for Vaccines and Immunization (GAVI) has been extraordinarily successful in mobilizing new support for the purchase
and deployment of needed vaccines in the public-health programs of developing countries and has recently launched support for research on new
vaccines and vaccine technologies. In addition, various organizations such as the Bill & Melinda Gates Foundation and the United States National
Institutes of Health are committing greatly increased resources for vaccine research and development. There have been major changes in the
vaccine industry both in developed and developing countries. With respect to the latter, an ongoing story of great import is the astonishing
evolution of many producers in developing countries.
During the years since the IVI was established in 1997, the Institute has become an important partner in global efforts to develop and deploy new
vaccines for the poor. It has launched major programs of field research on new vaccines against diarrheal, respiratory, and flavivirus infections in
21 countries of Asia, Africa and Latin America. It has also provided technical assistance in vaccine production, regulation, and evaluation to
professionals in 15 countries in Asia, Africa, and Latin America.
The IVI's growth has been made possible by generous support from an increasing number of donors. The Republic of Korea has played a pivotal
role in this respect, providing a portion of the IVI's operating budget, as well as a new headquarters building with state-of-the-art laboratories. The
recent completion of this beautiful building, located on the campus of Seoul National University, has allowed the Institute to launch an exciting new
laboratory sciences program that will greatly increase the IVI's ability to contribute to the enterprise of bringing vaccines to developing countries.
In closing, I would like to acknowledge the importance to our programs of the collaboration of many institutions and individuals, from both the
private and public sectors and from both the industrialized and developing worlds. And I would like to thank especially the scientists, public-health
officials, and other collaborators in developing countries who have allowed us to join with them in their work to reduce morbidity and mortality in
their countries. It has been an honor to have shared the hopes and aspirations of these dedicated persons.
Sincerely,
3
Letter from the Director
John Clemens
At the United Nations Millennium Summit in September 2000 world leaders placed development at the heart of the global agenda by adopting the
Millennium Development Goals (MDGs), which set clear targets for reducing poverty, hunger, disease, illiteracy, environmental degradation, and
discrimination against women by 2015. The eight Millennium Development Goals constitute an ambitious agenda to significantly improve the
human condition by 2015. The IVI is actively working to make a valuable contribution to achieving the MDGs.
Millennium Development Goal 1, "Eradicate extreme poverty and hunger". By preventing unnecessary deaths and allowing
people, especially children, to lead healthy lives, the IVI contributes to alleviating poverty and strengthening economies.
Millennium Development Goal 4, "Reduce child mortality". The research programs at the IVI contribute to the target of
reducing by two-thirds, between 1990 and 2015, the under-five mortality rate by addressing new-generation vaccines against diarrhea and
respiratory infections, and against Japanese encephalitis and dengue fever. Together these diseases claim the lives of nearly five million persons
each year, most of whom are children living in impoverished conditions in developing countries.
Millennium Development Goal 8, "Develop a global partnership for development". The mission of the IVI is to develop and
accelerate the introduction of new vaccines at affordable prices into the public-health programs of developing countries. The IVI facilitates transfer
of vaccine technology to pharmaceutical companies in developing countries to create cost-effective vaccines for the world's poor. The Institute also
provides training and technical assistance for the clinical evaluation of vaccines and vaccine production and regulation to professionals in
developing countries.
4
The IVI and the Millenium Development Goals
Goal
The International Vaccine Institute is founded on the belief that the health of children in developing countries can be dramatically improved by the development, introduction, and use of new and improved vaccines and that these vaccines should be developed through a dynamic interaction among science, public health, and industry.
Mission
The International Vaccine Institute will contribute to the reduction of vaccine preventable diseases in developing countries by collaborative research that generates the evidence needed for rational introduction of new vaccines, supported by programs of basic and applied laboratory research, product development, training, and technical assistance.
Goal and Mission
September 2004 Kwon Yang-suk, First Lady of Korea, becomes the Honorary President of the Korea Support
Committee for the IVI.
July 2003 Launch of the Pediatric Dengue Vaccine Initiative (PDVI) with a $55 million grant from Bill & Melinda
Gates Foundation.
June 2003 The IVI Board of Trustees elects Prof. Samuel Katz as its new chairman.
June 2003 Opening of the new headquarters building, generously donated by the Government of Korea, and initiation
of the IVI's new Laboratory Sciences Division.
March 2002 The Board of Trustees meet with Kim Dae-jung, President of the Republic of Korea, at the presidential
office at Cheong Wa Dae.
January 2000 Launch of the Diseases of the Most Impoverished (DOMI) Program with a $40 million grant from
Bill & Melinda Gates Foundation.
April 1999 Lee Hee-ho, First Lady of Korea, becomes the Honorary President of the Korea Support Committee
for the IVI.
April 1999 The Board of Trustees appoints Dr. John Clemens as the first Director of the IVI.
January 1999 The National Assembly of the Republic of Korea ratifies the Headquarters Agreement between the IVI
and the Republic of Korea, bringing it into full effect.
October 1997 Inaugural meetings of the governing Board of Trustees and the Institute Support Council convene
in Seoul, with Prof. Barry Bloom as the Board's first Chairman. The Board approves the first Strategic Plan for the IVI.
May 1997 The IVI's establishment goes into effect after receiving three ratifications at United Nations Headquarters in
New York.
December 1995 The Government of Korea (Ministry of Education and Human Resources Development) sets up
special task force at Seoul National University for the establishment of the IVI (Chaired by Prof. Park Sang Dai).
April 1995 First meeting of the Advisory Board of Trustees at the United Nations Development Programme (UNDP)
Headquarters in New York.
January 1995 UNDP opens an interim office of the IVI on the campus of Seoul National University in Seoul,
the Republic of Korea.
September 1994 The Administrator of UNDP and the Permanent Representative of the Republic of Korea to the
United Nations exchange letters confirming the designation of the Republic of Korea as the host country of the IVI.
June 1994 The Site Selection Committee, meeting at UNDP, recommends that the IVI be located in Seoul,
the Republic of Korea, and that the Institute carry out its activities through close partnerships with centers of excellence
in other countries in the region.
March 1994 Six Asian countries submit proposals to UNDP to host the IVI.
September 1993 Based on a feasibility study, a formal proposal to establish the IVI in a developing country in
Asia is adopted by UNDP.
September 1990 The World Summit on Children at the United Nations adopts a declaration calling for
concerted international action to promote children's health in developing countries, eventually leading to the creation of the
Children's Vaccine Initiative (CVI).
5
Historical Landmarks
6
Board of TrusteesProf. Samuel Katz - Chairman Professor Emeritus, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA
Dr. Michel Greco Former President, Aventis Pasteur, Lyon, France
Mr. Joon Oh Director General,Office of Policy Planning and International Organizations, Ministry of Foreign Affairs & Trade, Seoul, Republic of Korea
Dr. Shigeru Omi Regional Director,WHO Regional Office for the Western Pacific (WPRO), Manila, The Philippines
Dr. Samlee Plianbangchang Regional Director, WHO Regional Office for South-East Asia (SEARO),New Delhi, India
Dr. George Poste Director, The Biodesign Institute at Arizona State University,Tempe, Arizona, USA
Prof. Philip K. Russell Professor Emeritus, Johns Hopkins Bloomberg School of Public Health,Baltimore, Maryland, USA
Prof. Ian David Gust Professor Emeritus,University of Melbourne, Victoria, Australia
Dr. Nay Htun Professor and Executive Director,University for Peace, New York, USA
Prof. Paul-Henri Lambert Professor, Department of Pathology, University of Geneva,Geneva, Switzerland
Dr. Hanna Maria Nohynek Department of Vaccines, National Public Health Institute, Helsinki, Finland
Prof. Jan Holmgren - Vice Chairman Professor,Department of Medical Microbiology & Immunology,University of Gothenburg, Gothenburg, Sweden
Prof. Maharaj Krishnan Bhan Secretary,Department of Biotechnology, Ministry of Science and Technology, New Delhi, India
Dr. John D. Clemens Director, International Vaccine Institute, Seoul, Republic of Korea
Prof. Gordon Dougan Professor,Center for Molecular Microbiology and Infection, Department of Biological Science, Imperial College of Science, Technology and Medicine, London, United Kingdom
From the left to right in the first row, Dr. John D. Clemens, Prof. Sam L. Katz, Dr. Hanna Maria Nohynek, Prof. Myung-Hee Chung, Dr. Shigeru Omi, Mr. Joon Oh
In the second row, Prof. Margaret Liu, Prof. Geoffrey Schild, Dr. Michel Greco, Prof. Ian David Gust, Prof. Philip Russell, Prof. Gordon Dougan, Prof. Jan Holmgren, Prof. Paul-Henri Lambert
Prof. Margaret Liu, the Chairperson of SAG, is at the head of table in the SAG meeting held at IVI headquarters in 2003.
The IVI Scientific Advisory Group (SAG), established in 2000, is composed of international experts in vaccine sciences and public health. The SAG meets yearly to review the scientific
programs of the Institute and to advise the Director.
Prof. Michael Good Director, Queensland Institute of Medical ResearchBrisbane, Australia
Dr. Costante Ceccarini Independent Consultant,Vaccine Research and Development, Sienna, Italy
Prof. Margaret Liu - Chairperson Vice-Chairman, Transgene, Lyon, France, and Visiting Professor, Karolinska Institute, Stockholm, Sweden
Prof. Robert E. Black Chairman, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore,
Prof. Moon Nahm Professor,Department of Pathology,University of Alabama School of Medicine,Birmingham, Alabama,USA
Prof. Sun Young Kim Professor,Institute of Molecular Biology and Genetics,Seoul National University, Seoul, Republic of Korea
Prof. Stefan Kaufmann Director,Department of Immunology,Max Planck Institute for Infection Biology, Berlin, Germany
Prof. Yoshifumi Takeda Professor,Department of Food and Health SciencesJissen Women's University, Tokyo, Japan
Prof. Rho Hyun Seong Associate Professor,Institute of Molecular Biology & Genetics,Seoul National University, Seoul, Republic of Korea
Prof. Peary L. Ogra Professor Emeritus,Department of Pediatrics,State University of New York at Buffalo, Buffalo, New York, USA
Dr. Elwyn Griffiths Associate Director, General Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Canada
Scientific Advisory Group
7
Signatory Countries
World HealthOrganizationVietnam�TurkeyThailandTajikistanSwedenSri Lanka
SlovakRepublic
SenegalRomaniaPanamaPakistanOman
NetherlandsNepalMyanmar Mongolia�MaltaLebanon
Jamaica�IsraelIndonesiaEcuador EgyptChinaBrazilBhutanBangladesh
Yearly Budget and Personnel Graph
1997 19992001
2003
2005(projected)
2005(projected)
105
93
70
50
40
30
1012
18
18,000,000
1997 19992001
2003
16,000,000
14,000,000
12,000,000
10,000,000
8,000,000
4,000,0006,000,000
2,000,000
Recent Growth
8
Budget Growth since 1997Staff Growth since 1997
Republic ofKorea
Kazakhstan Kuwait� Kyrgyzstan�
Papua New Guinea Peru�
Uzbekistan
The IVI has experienced rapid growth in its budget and staff since its creation in 1997 Its staff now numbers 93 and comes from
16 countries in Asia, Africa, Europe, North America, and Australia.
Philippines�
IVI s Achievements
Organizational Structure
Since its establishment in 1997, the IVI has:
9
Established major research programs in 21 countries of Asia, Africa and Latin America
- Determine the disease burden of invasive bacterial infections of childhood, especially Haemophilus influenzae type b (Hib)
- Assess the disease burden of rotavirus diarrhea in children
- Accelerate the development and provide evidence for rational introduction of vaccines against cholera, shigellosis,
and typhoid fever (the Diseases of the Most Impoverished Program)
- Accelerate the development and introduction of new vaccines against dengue fever for public-health programs
for the poor in Asia and Latin America (The Pediatric Dengue Vaccine Initiative)
- Provide evidence for the rational introduction of vaccines against Japanese encephalitis into programs for children in Asia
- Assess the efficacy of new vaccines against enterotoxigenic Escherichia coli
- Develop model systems for assessing the safety of vaccines used in developing countries
Initiated a program of laboratory research at the IVI headquarters in Seoul that addresses topics in immunology,
molecular microbiology, and vaccine development and process research.
Provided training and technical assistance to professionals in Asia and Africa on:
- Clinical evaluation of vaccines
- Vaccine production and regulation
Established a group of affiliated laboratories in Korea and a network of collaborating laboratories in
Europe and the United States.
Established a post-doctoral training program in the network of IVI's collaborating laboratories.
BOARD OF TRUSTEES
TRANSLATIONALRESEARCH LABORATORY SCIENCES
DEPUTY DIRECTOR
ADMINISTRATION ANDFINANCE
DEPUTY DIRECTOR
COMPUTER SERVICES
ACCOUNTING ANDFINANCE
BUILDING ANDMAINTENANCE
HUMAN RESOURCESAND ADMINISTRATIVESUPPORT SERVICES
LIBRARY ANDINFORMATION
SERVICES
IMMUNOLOGY
MOLECULARMICROBIOLOGY
VACCINEDEVELOPMENT
HEAD
EPIDEMIOLOGY ANDCLINICAL TRIALS
BIOSTATISTICS
DATA MANAGEMENT
PROGRAM SUPPORT
ECONOMICS,SOCIOBEHAVIORAL AND
POLICY RESEARCH
DIRECTOR
INSTITUTE SUPPORT COUNCIL
OFFICE OF THE ASSOCIATE DIRECTOR FOR PROGRAMS, PARTNERSHIPS, AND
INSTITUTIONAL DEVELOPMENT
INSTITUTIONAL REVIEW BOARD SCIENTIFIC ADVISORY GROUP SPECIAL ADVISORS
Translational Research Division
Divisions of the IVI
10
Activities (countries participating):
- Epidemiologic studies of disease burden (Brazil, Cambodia, El Salvador, Malaysia, Panama, Thailand, Venezuela)
- Development of field sites for cohort studies and preparation for vaccine trials (Nicaragua)
- Policy research on vaccine introduction (Cambodia, Indonesia, Thailand, Vietnam)
- Research to develop tests that predict the risk of dengue hemorrhagic fever and the molecular basis of dengue pathogenisis
2. The Pediatric Dengue Vaccine Initiative (PDVI)
Donor support: Bill & Melinda Gates Foundation; Ministry of Education and Human Resources Development, Republic of Korea;
Rockefeller Foundation.
Goal: The Pediatric Dengue Vaccine Initiative (PDVI) is a program of research designed to provide the evidence needed to accelerate the
development and begin the introduction of new vaccines against dengue fever into public-health programs for children in developing countries.
Activities (countries participating):
- Epidemiologic studies of disease burden (Bangladesh, China, India, Indonesia, Mozambique, Pakistan, Thailand, Vietnam)
- Clinical trials of experimental vaccines (Bangladesh, India,Vietnam)
- Demonstration projects of existing vaccines (China, India, Indonesia, Mozambique, Pakistan, Vietnam)
- Studies of the economic cost of illness and of the cost-effectiveness of vaccinating (Bangladesh, China, India, Indonesia,
Mozambique, Pakistan, Thailand, Vietnam)
- Sociobehavioral studies of perceptions of Cholera, Shigellosis, and typhoid fever and the need for vaccination (Bangladesh, China, India, Indonesia,
Pakistan, Thailand, Vietnam)
- Policy research on vaccine introduction (Bangladesh, China, India, Indonesia, Mozambique, Pakistan, Thailand, Vietnam)
- Technical assistance in vaccine research and production (Bangladesh, China, India, Indonesia, Mozambique, Pakistan, Thailand, Vietnam)
- Vaccine-production technology transfer (China, India, Indonesia, Pakistan, Vietnam)
1. Diseases of the Most Impoverished (DOMI) Program
Donor support: Bill & Melinda Gates Foundation; Japan International Cooperation Agency; Ministry of Education and Human Resources
Development, Republic of Korea; GlaxoSmithKline; Sartorius; Wellcome Trust Labs.
Goal: The Diseases of the Most Impoverished (DOMI) Program is a program of research, technical assistance, and technology transfer for vaccine
production designed to accelerate the rational introduction of new-generation vaccines against cholera, shigellosis, and typhoid fever into public-health
programs of selected developing countries in Asia and Africa.
The Translational Research Division of the IVI conducts the diverse types of research needed to provide the evidence required by policy makers to introduce new vaccines into public-health programs for the poor in developing countries. These studies include assessments of the disease burden and risk factors for specific diseases in different populations; clinical trials and demonstration projects of vaccines; economic analyses of the cost-effectiveness of introducing new vaccines; behavioral assessments of the public demand and willingness to pay for new vaccines; and policy assessments of the feasibility and financial sustainability of introducing new vaccines. The multidisciplinary group of scientists in this division include experts in epidemiology, clinical trials, computer sciences, biostatistics, economics, behavioral sciences, and policy analysis.
Activities (countries participating):
- Studies of the disease burden and economic costs of rotavirus diarrhea (Cambodia, China, Korea, Laos, Mongolia, Sri Lanka, Vietnam)
- Studies of the background incidence of intussusception, against which the safety of future rotavirus vaccines can be measured (China, Vietnam)
6. Program on New Systems for Assessing Vaccine Safety in Developing Countries
Donor support: Government of Japan; Ministry of Education and Human Resources Development, Republic of Korea;
United Nations Development Programme.
Goal: The Program on New Systems for Assessing Vaccine Safety in Developing Countries focuses on innovative methods for
monitoring vaccine safety and for assessing hypotheses about alleged vaccine side-effects in developing countries.
Activities (countries participating):
- Development of dynamic, large-linked databases for assessing rare but serious side-effects (Vietnam)
5. Program on the Introduction of Vaccines against Rotavirus Diarrhea
Donor support: The Children's Vaccine Program at PATH;Chiron; GlaxoSmithKline; Merck; Ministry of Education and Human Resources
Development, Republic of Korea; Wyeth.
Goal: The Program on the Introduction of Vaccines against Rotavirus Diarrhea conducts research to provide the evidence needed for the
introduction of new vaccines against childhood rotavirus diarrhea into routine infant immunization programs.
Translational Research Division
Activities (countries participating):
- Epidemiologic studies of the disease burden (Cambodia, India, Indonesia, Vietnam)
- Clinical studies of long-term neurobehavioral sequelae (China)
- Demonstration projects of existing vaccines (Vietnam)
- Studies of the economic cost of illness and of the cost-effectiveness of vaccinating (China, Indonesia, Thailand, Vietnam)
- Policy research on vaccine introduction (China, Indonesia, Thailand, Vietnam)
3. Japanese Encephalitis Vaccine Program
Donor support: Korea International Cooperating Agency (KOICA); Ministry of Education and Human Resources Development, Republic of
Korea; The Children's Vaccine Program at PATH.
Goal: The Japanese Encephalitis Vaccine Program is a program of research to provide the evidence necessary for rational policies on the
introduction of vaccines against Japanese encephalitis into public-health programs for poor populations living in developing countries of Asia.
Activities (countries participating):
- Studies of the disease burden of bacterial meningitis (China, Korea, Vietnam)
- Studies of the disease burden of bacterial pneumonia (China, Korea, Vietnam)
4. Program on Vaccines for Invasive Bacterial Diseases of Childhood
Donor support: Aventis Pasteur; The Children's Vaccine Program at PATH;Chiron; GlaxoSmithKline; Merck; Ministry of Education and
Human Resources Development, Republic of Korea; Wyeth.
Goal: The Program on Vaccines for Invasive Bacterial Diseases of Childhood seeks to provide an improved evidence base of disease-burden
statistics to assist the rational introduction of new-generation vaccines against Haemophilus influenzae type b, Streptococcus pneumoniae, and
Neisseria meningitidis into public-health programs for children in Asia.
11
2. Laboratory of Mucosal Immunology
Donor support: Japan Society for the Promotion of Science; Korea Science and Engineering Foundation; Ministry of Education and Human
Resources Development, Republic of Korea; Swedish International Development Cooperation Agency.
Goal: This laboratory conducts research to better understand fundamental aspects of the mucosal immune response and to exploit this
information to develop effective vaccines that can be administered without needles.
Activities:
- Characterization of the basic mucosal immune system during bacterial invasion
- Development of novel mucosal delivery systems and adjuvants
- Investigation of knock-out mice to define new immune correlates of protection
1. Laboratory of Cellular and Humoral Immunology
Donor support: Bill & Melinda Gates Foundation; Korea Research Institute of Bioscience and Biotechnology; Microscience;
Ministry of Education and Human Resources Development, Republic of Korea; Swedish International Development Cooperation Agency.
Goal: This laboratory focuses on developing assays to evaluate the immune responses in humans after vaccination in clinical and field trials.
The aim of this laboratory is to investigate the immunity induced by both parenteral and mucosal vaccines against bacterial diseases, with a
particular emphasis on vaccines against cholera and typhoid fever. Particular attention is devoted to simplifying assays in order that they can
be adapted to laboratories in developing countries and used for pediatric vaccines studies in these settings.
Activities:
- Assessment of antibacterial cell-mediated immunity
- Evaluation of antibody responses to both bacterial protein and non-protein antigens
- Development of improved tests for evaluating immunological memory at the B and T cell level
The Laboratory Sciences Division of the IVI was initiated in 2003, upon completion of the new headquarters building. The division undertakes diverse research to accelerate the development, evaluation, and introduction of new vaccines into developing countries, and prioritizes research that will support the research being undertaken by the Translational Research Division. Current major areas of emphasis include immunology (humoral, cellular, and mucosal); molecular microbiology; and vaccine development. The division currently employs 20 PhDs and research assistants operating in 5,000 square meters of laboratories equipped with state-of-the-art instruments.
Laboratory Sciences Division
12
3. Laboratory of Molecular Microbiology
Donor support: Korea Research Foundation; Ministry of Education and Human Resources Development, Republic of Korea; Ministry
of Science and Technology, Republic of Korea; Science and Engineering Foundation; Swedish International Development Cooperation
Agency.
Goal: This laboratory uses molecular biology techniques and bioinformatics to better understand the molecular epidemiology,
pathogenetic mechanisms, and genetic diversity of bacterial pathogens, with a special focus on Vibrio cholerae, Salmonella, and
Shigella,
in order to devise improved vaccine strategies for developing countries.
Activities:
- Molecular epidemiology studies in developing countries
- Basic research on pathogenesis
- Development of improved, computerized information management systems for analysis of genomic information
- Database generation and analysis of genome information on human isolates
- Development of novel vaccine approaches for DNA vaccines
4. Laboratory of Vaccine Development
Donor support: AusAID; Bill & Melinda Gates Foundation; Ministry of Education and Human Resources Development, Republic of
Korea;Sartorius AG; Swedish International Development Cooperation Agency.
Goal: The goals of this laboratory are to develop, improve, and transfer to local producers the manufacturing and quality-control
technologies needed for vaccines against diseases of developing countries.
Activities:
- Development of a subunit Shigella vaccine
- Scaled-up development of a Vi polysaccharide-protein conjugate vaccine against typhoid fever
- Development of improved manufacturing processes for killed, oral cholera vaccine
- Technical assistance in the manufacture of killed, oral cholera vaccine for manufacturers in Vietnam, Indonesia, India, China,
and Pakistan
- Technical assistance in the manufacture of Vi polysaccharide vaccine against typhoid fever for manufacturers in Vietnam,
Indonesia, India, China, and Pakistan
Laboratory Sciences Division
13
Training and Technical Assistance Division
Donor support: AusAID; Bill & Melinda Gates Foundation; GlaxoSmithKline; Ministry of Education and Human Resources Development, Republic of Korea; Rockefeller Foundation; Sartorius.Goal: The Training and Technical Assistance Division provides training on modern methods and standards for vaccine production and evaluation, as well as on research methods needed to generate evidence for vaccine policy. As well, the division provides techical assistance to producers in developing countries for the production of new vaccines. The division participates as a trainer in the Global Training Network of the World Health Organization.
Activities (countries participating):
- Training on Good Manufacturing Practices in vaccine production (China, Vietnam)
- Training on production and lot of release testing of killed, oral cholera and Vi polysaccharide vaccines (China, Vietnam,
India, Indonesia, Pakistan)
- Training on Good Clinical Practice standards and methods for trials of vaccines in humans (Bangladesh, Cambodia, China, India, Indonesia,
Pakistan, Philippines, Thailand, Vietnam)
- Post-doctoral training in vaccine sciences (France, Korea, Sweden, United States)
- Annual international course on the principles of vaccinology (Bangladesh, Cambodia, China, Egypt, India, Indonesia, Mozambique, Pakistan,
Philippines, Thailand, Vietnam)
- Workshops on data management methods, microbiological techniques, and social science methods for field studies of vaccines (Bangladesh,
China, India, Indonesia, Mozambique, Pakistan, Thailand, Vietnam)
14
Future Directions of the IVI
15
Expand program priorities to include additional diseases of importance, such as tuberculosis and emerging respiratory viruses
Extend field research into additional countries of Asia and Africa
Initiate a vaccine evaluation unit in the Clinical Trials Center of Seoul National University
Enlarge the laboratory programs on immunology, molecular microbiology, and chemistry
Create a laboratory of molecular virology to detect and characterize emerging viruses
Establish improved tests for evaluating immunological responses to vaccines in children in developing countries
Develop methods for molecular characterization of known bacterial pathogens under field conditions
Develop new or improved vaccines against Shigella, cholera, and typhoid
Facilitate technology transfer of production of new vaccines to qualified producers
Participate in training in vaccine production and regulation as part of the WHO Global Training Network
Organize periodic courses on the clinical evaluation of vaccines, Good Clinical Practices for vaccine trials, computerized approaches to data
management, and the design and conduct of economic, sociobehavioral, and policy analyses of vaccine introduction
Conduct national and international symposia and workshops on scientific topics of relevance to vaccines for developing countries
1. Translational Research
2. Laboratory Research and Vaccine Development
3. Training and Information Dissemination
Korea Support CommitteeA large number of prominent Korean citizens have joined together to form the Korea Support Committee for the IVI. The Committee is a vehicle for mobilizing resources within Korea. It is under the leadership of Korea's First Lady, Ms. Kwon,Yang-suk.
Core funding to the IVI is provided by the governments of Korea and Sweden. In addition, donors from the public and the private sector provide support for the Institute's research and technical assistance activities.
AusAID
Bill & Melinda Gates Foundation
Children's Vaccine Program ot PATH
Industry (Aventis Pasteur, Berna Biotech, CJ, Chiron,
GlaxoSmithKline, LG, Merck,Microscience, Nonghyup,
Sartorius, Wyeth)
Japan International Cooperation Agency
Japan Society for the Promotion of Science
Korea International Cooperation Agency (KOICA)
Korea Research Foundation
Korea Research Institute of Bioscience and Biotechnology
Korean Science and Engineering Foundation
Ministry of Education & Human Resource Development,
Republic of Korea
Rockefeller Foundation
Swedish International Development Cooperation Agency
UBS Optimus Foundation
United Nations Development Programme (UNDP)
U.S. National Institutes of Health
Wellcome Trust Labs,HoChiMinh city
Donors to the IVI
16
Korea: Catholic University, St. Paul's Hospital and St. Mary's
Hospital; Changwon Fatima Hospital; Chonbuk National
University; Chonbuk Provincial Department of Health; Chonju
Presbyterian Medical Center; Green Cross Reference
Laboratory; Hallym University Medical Center; Hanyang
University Hospital; Inha University Hospital; Cheju National
University Hospital; Jung-Eub Hospital; Korea Research Institute
of Bioscience and Biotechnology; Korea University; Korea Food
and Drug Administration; Korean National Institute of Health;
Kyung Hee University Medical Center; LG Life Sciences;
Namwon Medical Center; Pohang University of Science and
Technology; Pusan National University Hospital; Samkwang
Reference Laboratories; Seoul Clinical Laboratories; Seoul
National University; Samsung Medical Center; Social Security
Research Institute; SoonChunHyang University Hospital; Ulsan
University; Wonkwang University Medical Center; Yonsei
University
Japan: National Institute of Infectious Diseases; Osaka
University; Research Institute for Microbial Diseases, The
Institute of Medical Science, The University of Tokyo.
Indonesia: Bio Farma; Centers for Disease Control; Central
Public Health Laboratory; National Institute of Health Research
and Development; Udayana University; U.S. Naval Medical
Research Unit 2
India: All India Institute of Medical Sciences; Indian Council of
Medical Research; International Center for Genetic Engineering
and Biotechnology; National Institute of Cholera and Enteric
Diseases; Shantha Biotechnics
Germany: Sartorius Group
France: Aventis Pasteur; Epicentre; Institut Pasteur
Finland: National Public Health Institute
Egypt: Ministry of Health and Population; U.S. Naval Medical
Research Unit 3; Vacsera
China: An Hui Province Anti-Epidemic Station; Beijing Friendship
Hospital; Changchun Children's Hospital; Centers for Disease
Control; Dongnan University School of Public Health; Fudan
University; Guangxi Maternal and Child Hospital; Guangxi Medical
University; Guangxi Province Anti-Epidemic Center; Guangxi
Provincial Hospital; Hebei Province Anti-Epidemic Station; Jiangsu
Province Anti-Epidemic Station; Kunming Children's Hospital;
Lanzhou Institute of Biological Products; Lulong County Health
and Anti-Epidemic Center; Ma-An-Shan Hospital; Nanning Second
City Hospital; Sinovac Biotech; Suzhou Medical School; Wuhan
Institute of Biological Products; Wuming County Hospital; Yongning
County Hospital
Canada: Health Canada; University of Western Ontario
Cambodia: Communicable Disease Control, Ministry of Health;
Kantha Bopha Children's Hospital; National Immunization
Program, Ministry of Health; National Pediatric Hospital
Belgium: GlaxoSmithKline Biologicals
Bangladesh: ICDDR,B; Center for Health and Population
Research; Dhaka Shishu Hospital
Australia: The Queensland Institute of Medical Research
International Collaborators
17
Sweden: Swedish Bacteriological Laboratory; University of
Gothenburg
Sri Lanka: Epidemiology Unit, Ministry of Health; Lady
Ridgeway Hospital
International: World Health Organization
Vietnam: Bach Mai Hospital; Hanoi Health Service; Ha Tay
Province Preventive Medicine Center; HoChiMinh Pasteur
Institute; Hue City Hospital; Hue Province Preventive Medicine
Center; Institute of Vaccines and Biological Substances; Khanh
Hoa Provincial Hospital; National Institute of Hygiene and
Epidemiology; National Institute of Pediatrics; Nha Trang Pasteur
Institute; Ninh Hoa District Hospital; Phu Tho Province Center for
Preventive Medicine; Phu Tho Provincial Hospital; VaBiotech;
Wellcome Trust , Center for Tropical Diseases, HoChiMinh City
United States: Arizona State University; Brandeis University;
California Institute of Technology; Center for Biologics Evaluation
and Research, Food and Drug Administration; Centers for
Disease Control and Prevention; Chiron; Colorado State
University; Harvard University; Johns Hopkins University; Merck;
National Institutes of Health; Naval Medical Research Center;
Portland University; Program for Appropriate Technology in
Health; Purdue University; University of Alabama; University of
California at Berkeley; University of California at Los Angeles;
University of Maryland; University of North Carolina at Chapel Hill;
University of Pennsylvania; University of Rochester Medical
Center; University of Texas Medical Branch at Galveston; Walter
Reed Army Institute of Research; Washington University; Wayne
State University; West Virginia University; Wyeth
United Kingdom: Wellcome Trust Sanger Institute; Health
Protection Agency; Imperial College London; London School of
Hygiene & Tropical Medicine; Microscience; National Institute of
Biological Standards and Control
Thailand: Armed Forces Research Institute of Medical
Sciences; Center for Disease Control, Ministry of Public Health;
Mahidol University
Singapore: K.K. Women's and Children's Hospital
Philippines: Cebu Institute of Medicine; Research Institute for
Tropical Medicine
Pakistan: Aga Khan University; Amson Pharmaceuticals
Mozambique: Ministry of Health
Mongolia: Maternal and Child Health Research Center,
Ministry of Health
Laos: Mahosot Hospital; National Institute of Public Health,
Ministry of Health
18
Switzerland: Berna Biotech; Medecins Sans Frontieres; World
Health Organization